Form 4: Alpha Cognition Inc. Officer Awarded Stock Options

Lauren D'Angelo, Chief Operating Officer of Alpha Cognition Inc., was granted stock options exercisable for 298,168 common shares.

Summary

• Lauren D'Angelo, the Chief Operating Officer of Alpha Cognition Inc., filed a Form 4 indicating a change in beneficial ownership.
• The transaction involved the acquisition of options to purchase 298,168 common shares of Alpha Cognition Inc. at an exercise price of $5.93.
• These options were granted on February 25, 2025, and expire on February 25, 2035.
• The options vest over 36 months, with 12.5% vesting immediately and the remainder vesting quarterly.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and indicates confidence in the executive's ability to contribute to the company's success. There is no negative information presented.

Positives

• The grant of stock options to the COO aligns her interests with those of the shareholders.
• The vesting schedule incentivizes long-term performance and commitment from the COO.

Industry Context

Stock option grants are a common practice in the pharmaceutical and biotechnology industries to incentivize executives and align their interests with shareholders. This grant is typical for a COO role in a company like Alpha Cognition.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Biogen, Amgen, and Gilead Sciences routinely grant stock options to their executives as part of their overall compensation strategy.
• The vesting schedule of 36 months with a combination of cliff and quarterly vesting is also a common practice.

Stakeholder Impact

• Shareholders may view the option grant positively as it incentivizes the COO to improve company performance.
• Employees may see this as a positive sign of investment in leadership.

Key Dates